文献速递胃肠外科围术期管理与 ERAS

利拉鲁肽使用与袖状胃切除术后胃胰粘连发生率

Incidence of adhesions in patients using liraglutide before laparoscopic sleeve gastrectomy.
PubMed 文献 · Surg Endosc · 2022-04-29

这项前瞻性观察研究在沙特阿拉伯SGH普通外科开展,纳入117例既往使用利拉鲁肽和101例未使用利拉鲁肽的LSG患者,术中腹腔镜评估胃后壁与胰腺之间粘连。结果显示病例组22.2%存在粘连,对照组未见粘连(p < 0.001)。

要点

  • 既往使用利拉鲁肽的LSG患者中22.2%存在胃胰粘连,对照组无粘连(p < 0.001)。
  • 病例组48.7%患者无明确原因停用利拉鲁肽。
  • 行LSG时对有利拉鲁肽暴露史者应警惕粘连可能,需仔细分离。

核心结论

  • 首次报道既往使用利拉鲁肽的LSG患者胃胰粘连发生率为22.2%(p < 0.001),提示利拉鲁肽暴露者行LSG时可能存在粘连。

研究设计与样本

  • 观察性前瞻性研究,在沙特阿拉伯SGH普通外科开展,经机构审查委员会批准,纳入117例既往使用利拉鲁肽和101例未使用利拉鲁肽的LSG患者,为期12个月。

主要发现

  • 病例组平均年龄32.44 ± 9.90岁 vs 对照组28.23 ± 8.48岁(p = 0.001)。
  • 病例组平均BMI 43.56 ± 4.59 vs 对照组45.00 ± 4.78(p = 0.024)。
  • 病例组女性85%、男性17.0%;对照组女性53.5%、男性47.0%(p < 0.001)。
  • 病例组48.7%患者无明确原因停用利拉鲁肽。
  • 病例组77.8%无粘连、22.2%有粘连;对照组未见粘连(p < 0.001)。

临床怎么用

  • 对既往有利拉鲁肽暴露史的LSG患者,术者应知晓粘连可能性,需仔细精准分离。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The current study objectively identified the incidence of adhesions between the stomach and pancreas in laparoscopic sleeve gastrectomy (LSG) patients on liraglutide (cases group) and off (control group) liraglutide. METHODS: This observational prospective study was conducted in the Department of General Surgery at Saudi German Hospital, Al-Aseer, Saudi Arabia (SGH) after approval by the Institutional Review Board. 117 patients with prior use of liraglutide and 101 patients with no liraglutide use scheduled for LSG over 12 months were included. Inclusion criteria included patients undergoing LSG with or without prior use of liraglutide. Exclusion criteria included patients with prior abdominal surgeries, bariatric surgery revisions, prior upper GI scope showing gastritis, Gastroesophageal Reflux Disease (GERD) or any other pathology, and other known causes of other causes of pancreatitis. Using laparoscopy obtained imaging during LSG cases adhesions between the posterior stomach and pancreas were identified. RESULTS: The mean age of the patients in the cases and control groups was 32.44 ± 9.90 years and 28.23 ± 8.48 years (p = 0.001). The mean BMI of patients in the cases and control groups was 43.56 ± 4.59 and 45.00 ± 4.78, respectively (p = 0.024). 85% of the patients were females, while 17.0% were males in the cases group. 53.5% of the patients were females, while 47.0% were males in the control group (p < 0.001). In the cases group, 48.7% of patients had stopped liraglutide for no obvious reason. Under the cases group, 77.8% of the patients had no adhesions, while 22.2% had adhesions. Under the controls group, no adhesions were seen (p < 0.001). CONCLUSIONS: Our results for the first time demonstrate an incidence of adhesions in 22.2% of patients undergoing LSG on prior liraglutide intake (p < 0.001). This study brings to light the possibility of adhesions in patients with prior exposure to liraglutide undergoing LSG. Surgeons performing LSG in patients with prior exposure to liraglutide should be cognizant of this possibility, thereby requiring careful meticulous dissection.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Hakim M, Fathi M, Abdulraziq M, et al. Incidence of adhesions in patients using liraglutide before laparoscopic sleeve gastrectomy. Surg Endosc. 2022. PMID: 35488131. doi:10.1007/s00464-022-09294-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。